Cara Therapeutics appoints Lisa von Moltke, M.D. to Board of Directors

Tvardi Therapeutics, Inc.

Dr. von Moltke is EVP and Chief Medical Officer at Seres Therapeutics, with prior roles at Alkermes and Sanofi.
She will receive $45K annual cash retainer, $5K for nominating committee, and initial option grant of $350K vesting quarterly over 3 years.
Appointment effective November 1, 2022; term expires at 2023 Annual Meeting; she will serve on nominating and corporate governance committee.
Her expertise is expected to support execution of strategy for oral difelikefalin in pruritus, a key pipeline program.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lisa von Moltke, M.D.

Director

TVRD · Tvardi Therapeutics, Inc.

Effective: 2022-11-01
Filed: November 3, 2022, 7:59 PM ET

On November 1, 2022, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Lisa von Moltke, M.D. to serve as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa von Moltke, M.D. was appointed as Director at Tvardi Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 1, 2022, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Lisa von Moltke, M.D. to serve as a member of the Board

View on SEC.gov

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-114206

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.